Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs”, 09887) has issued a circular convening its Annual General Meeting for 10:00 a.m. on 15 May 2026 in Nanjing. Key items on the agenda are summarised below:
Financials and Profit Distribution • 2025 Final Financial Report and full Annual Report will be tabled for shareholder approval. • The Board recommends no final dividend for the year ended 31 December 2025, citing operating results, current financial position and future development plans.
Corporate Governance & Board Changes • Dr. Wu Fenglan, with more than 15 years’ biopharma experience, is nominated as a Non-Executive Director for the remainder of the first Board term (maximum three years). No director’s fee will be payable for the role. • Ernst & Young is proposed for re-appointment as auditor for 2026. Audit fees are estimated at RMB2.18 million–RMB2.68 million, subject to final scope. • The 2026 Directors’ Remuneration Plan will maintain the current compensation policy.
Capital Management Proposals • Share Issue Mandate: a 12-month general mandate allowing the Board to allot and issue up to 20% of total issued shares (excluding treasury shares). • Share Repurchase Mandate: authority to buy back up to 10% of issued H shares (excluding treasury shares) on the Hong Kong Stock Exchange within the same period. Repurchased shares may be cancelled or held in treasury in line with PRC regulations and HKEX rules. • Amendments to the Articles of Association are proposed to reflect updated regulatory requirements and housekeeping changes.
Administrative Details • The H-share register closes from 12 May to 15 May 2026. Shareholders must lodge transfer documents by 4:30 p.m. on 11 May 2026 to qualify for attendance and voting rights. • Proxy forms must be submitted no later than 10:00 a.m. on 14 May 2026.
All related documents, including the proxy form and detailed circular, are available on the HKEX news website and the company’s website.
Comments